These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 8547658)
1. Inhibition of myeloma cell growth by dexamethasone and all-trans retinoic acid: synergy through modulation of interleukin-6 autocrine loop at multiple sites. Chen YH; Desai P; Shiao RT; Lavelle D; Haleem A; Chen J Blood; 1996 Jan; 87(1):314-23. PubMed ID: 8547658 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of myeloma cell growth by all-trans retinoic acid is associated with upregulation of p21WAF1 and dephosphorylation of the retinoblastoma protein. Lavelle D; Chen YH; Hankewych M; Desimone J Leuk Lymphoma; 1999 Oct; 35(3-4):261-8. PubMed ID: 10706449 [TBL] [Abstract][Full Text] [Related]
3. Dexamethasone plus retinoids decrease IL-6/IL-6 receptor and induce apoptosis in myeloma cells. Smith MR; Xie T; Joshi I; Schilder RJ Br J Haematol; 1998 Sep; 102(4):1090-7. PubMed ID: 9734662 [TBL] [Abstract][Full Text] [Related]
4. Growth inhibition of a human myeloma cell line by all-trans retinoic acid is not mediated through downregulation of interleukin-6 receptors but through upregulation of p21(WAF1). Chen YH; Lavelle D; DeSimone J; Uddin S; Platanias LC; Hankewych M Blood; 1999 Jul; 94(1):251-9. PubMed ID: 10381520 [TBL] [Abstract][Full Text] [Related]
5. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. Sidell N; Taga T; Hirano T; Kishimoto T; Saxon A J Immunol; 1991 Jun; 146(11):3809-14. PubMed ID: 2033252 [TBL] [Abstract][Full Text] [Related]
6. Inhibitory effect of all-trans retinoic acid on the growth of freshly isolated myeloma cells via interference with interleukin-6 signal transduction. Ogata A; Nishimoto N; Shima Y; Yoshizaki K; Kishimoto T Blood; 1994 Nov; 84(9):3040-6. PubMed ID: 7949175 [TBL] [Abstract][Full Text] [Related]
7. Retinoic acid modulates the in vivo and in vitro growth of IL-6 autocrine human myeloma cell lines via induction of apoptosis. Levy Y; Labaume S; Colombel M; Brouet JC Clin Exp Immunol; 1996 Apr; 104(1):167-72. PubMed ID: 8603522 [TBL] [Abstract][Full Text] [Related]
8. The IL-6 receptor antagonist SANT-7 overcomes bone marrow stromal cell-mediated drug resistance of multiple myeloma cells. Hönemann D; Chatterjee M; Savino R; Bommert K; Burger R; Gramatzki M; Dörken B; Bargou RC Int J Cancer; 2001 Sep; 93(5):674-80. PubMed ID: 11477577 [TBL] [Abstract][Full Text] [Related]
9. How does interleukin-6 affect the membrane expressions of interleukin-6 receptor and gp130 and the proliferation of the human myeloma cell line OPM-2? Kovacs E Biomed Pharmacother; 2003 Dec; 57(10):489-94. PubMed ID: 14637393 [TBL] [Abstract][Full Text] [Related]
10. The gp 130 family cytokines IL-6, LIF and OSM but not IL-11 can reverse the anti-proliferative effect of dexamethasone on human myeloma cells. Juge-Morineau N; François S; Puthier D; Godard A; Bataille R; Amiot M Br J Haematol; 1995 Jul; 90(3):707-10. PubMed ID: 7647014 [TBL] [Abstract][Full Text] [Related]
11. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Tassone P; Neri P; Burger R; Savino R; Shammas M; Catley L; Podar K; Chauhan D; Masciari S; Gozzini A; Tagliaferri P; Venuta S; Munshi NC; Anderson KC Clin Cancer Res; 2005 Jun; 11(11):4251-8. PubMed ID: 15930364 [TBL] [Abstract][Full Text] [Related]
12. Mechanisms of inhibition of IL-6-mediated immunoglobulin secretion by dexamethasone and suramin in human lymphoid and myeloma cell lines. Shiao RT; McLeskey SB; Khera SY; Wolfson A; Freter CE Leuk Lymphoma; 1996 Apr; 21(3-4):293-303. PubMed ID: 8726410 [TBL] [Abstract][Full Text] [Related]
13. Multiple myeloma and B cell lymphoma. Investigation of IL-6, IL-6 receptor antagonist (IL-6RA), and GP130 antagonist (GP130A) using various parameters in an in vitro model. Kovacs E ScientificWorldJournal; 2006 Aug; 6():888-98. PubMed ID: 16892169 [TBL] [Abstract][Full Text] [Related]
14. Effects of all-trans retinoic acid (ATRA) on human myeloma cells. Otsuki T; Sakaguchi H; Hatayama T; Wu P; Takata A; Hyodoh F Leuk Lymphoma; 2003 Oct; 44(10):1651-6. PubMed ID: 14692515 [TBL] [Abstract][Full Text] [Related]
15. Establishment of a novel myeloma cell line KPMM2 carrying t(3;14)(q21;q32), which proliferates specifically in response to interleukin-6 through an autocrine mechanism. Goto H; Shimazaki C; Tatsumi T; Yamagata N; Fujita N; Tsuchiya M; Koishihara Y; Ohsugi Y; Nakagawa M Leukemia; 1995 Apr; 9(4):711-8. PubMed ID: 7723407 [TBL] [Abstract][Full Text] [Related]
16. Myeloma cell growth arrest, apoptosis, and interleukin-6 receptor modulation induced by EB1089, a vitamin D3 derivative, alone or in association with dexamethasone. Puthier D; Bataille R; Barillé S; Mellerin MP; Harousseau JL; Ponzio A; Robillard N; Wijdenes J; Amiot M Blood; 1996 Dec; 88(12):4659-66. PubMed ID: 8977259 [TBL] [Abstract][Full Text] [Related]
17. Characterization of an interleukin-6-mediated autocrine growth loop in the human multiple myeloma cell line, U266. Schwab G; Siegall CB; Aarden LA; Neckers LM; Nordan RP Blood; 1991 Feb; 77(3):587-93. PubMed ID: 1991169 [TBL] [Abstract][Full Text] [Related]
18. Regulation of insulin-like growth factor I production in rat C6 glioma cells: possible role as an autocrine/paracrine growth factor. Lowe WL; Meyer T; Karpen CW; Lorentzen LR Endocrinology; 1992 May; 130(5):2683-91. PubMed ID: 1572288 [TBL] [Abstract][Full Text] [Related]
19. Dexamethasone and suramin inhibit cell proliferation and interleukin-6-mediated immunoglobulin secretion in human lymphoid and multiple myeloma cell lines. Shiao RT; Miglietta L; Khera SY; Wolfson A; Freter CE Leuk Lymphoma; 1995 May; 17(5-6):485-94. PubMed ID: 7549842 [TBL] [Abstract][Full Text] [Related]
20. Oncostatin M, leukemia inhibitory factor, and interleukin 6 induce the proliferation of human plasmacytoma cells via the common signal transducer, gp130. Nishimoto N; Ogata A; Shima Y; Tani Y; Ogawa H; Nakagawa M; Sugiyama H; Yoshizaki K; Kishimoto T J Exp Med; 1994 Apr; 179(4):1343-7. PubMed ID: 8145046 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]